Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00023959
Status:
COMPLETED
Last Update Posted:
2013-02-07
First Post:
2001-09-13
Brief Title:
Bevacizumab Fluorouracil and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase I Study Of Bevacizumab Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy B-FHX For Poor Prognosis Head And Neck Cancer
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Monoclonal antibodies such as bevacizumab can block cancer growth in different ways Some block the ability of cancer cells to grow and spread Others find cancer cells and help kill them or deliver cancer-killing substances to them Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die Radiation therapy uses high-energy x-rays to damage tumor cells Combining monoclonal antibody therapy with chemotherapy and radiation therapy may be an effective treatment for head and neck cancer This phase I trial is to see if combining bevacizumab fluorouracil and hydroxyurea with radiation therapy works in treating patients who have advanced head and neck cancer
Detailed Description:
PRIMARY OBJECTIVES
I Determine the maximum tolerated dose and dose-limiting toxicity of bevacizumab when given in combination with fluorouracil hydroxyurea and radiotherapy in patients with advanced head and neck cancer
II Determine the time to progression pattern of failure local control and distant failure rate in patients treated with this regimen
III Determine the local toxic effects of this regimen in these patients
OUTLINE This is a multicenter dose-escalation study of bevacizumab
Patients receive oral hydroxyurea every 12 hours on days 1-6 fluorouracil IV continuously on days 1-5 and bevacizumab IV over 90 minutes on day 1 Patients also undergo radiotherapy once daily on days 1-5 Patients receive filgrastim G-CSF subcutaneously on days 6-12 Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity
Cohorts of 3-6 patients receive escalating doses of bevacizumab until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity Additional patients are treated at the MTD
PROJECTED ACCRUAL A total of 27-39 patients will be accrued for this study within 54-195 months
I Determine the maximum tolerated dose and dose-limiting toxicity of bevacizumab when given in combination with fluorouracil hydroxyurea and radiotherapy in patients with advanced head and neck cancer
II Determine the time to progression pattern of failure local control and distant failure rate in patients treated with this regimen
III Determine the local toxic effects of this regimen in these patients
OUTLINE This is a multicenter dose-escalation study of bevacizumab
Patients receive oral hydroxyurea every 12 hours on days 1-6 fluorouracil IV continuously on days 1-5 and bevacizumab IV over 90 minutes on day 1 Patients also undergo radiotherapy once daily on days 1-5 Patients receive filgrastim G-CSF subcutaneously on days 6-12 Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity
Cohorts of 3-6 patients receive escalating doses of bevacizumab until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity Additional patients are treated at the MTD
PROJECTED ACCRUAL A total of 27-39 patients will be accrued for this study within 54-195 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000068879 | REGISTRY | PDQ Physician Data Query | None |
| 11033B | None | None | None |